Legal & General Group
AMLX icon

Legal & General Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Legal & General Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$775K Sell
55,773
-16,839
-23% -$237K ﹤0.01% 2221
2025
Q4 		$877K Buy
72,612
+5,400
+8% +$73.3K ﹤0.01% 2258
2025
Q3 		$913K Buy
67,212
+59,810
+808% +$563K ﹤0.01% 2267
2025
Q2 		$47.4K Buy
+7,402
New +$36K ﹤0.01% 2718
2024
Q2 		– Sell
-32,854
Closed -$93.3K – 3416
2024
Q1 		$93.3K Sell
32,854
-6,812
-17% -$89.1K ﹤0.01% 2740
2023
Q4 		$584K Buy
39,666
+7,564
+24% +$116K ﹤0.01% 2395
2023
Q3 		$588K Buy
32,102
+3,586
+13% +$75.8K ﹤0.01% 2371
2023
Q2 		$615K Buy
28,516
+1,464
+5% +$39.5K ﹤0.01% 2393
2023
Q1 		$794K Buy
27,052
+22,029
+439% +$765K ﹤0.01% 2203
2022
Q4 		$186K Buy
5,023
+1,562
+45% +$55.4K ﹤0.01% 2639
2022
Q3 		$97K Buy
3,461
+2,237
+183% +$55.8K ﹤0.01% 2835
2022
Q2 		$24K Buy
1,224
+319
+35% +$3.79K ﹤0.01% 3168
2022
Q1 		$12K Buy
+905
New +$20.4K ﹤0.01% 3354

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Legal & General Group's AMLX Position: Q1 2026 in Review

Legal & General Group reduced its Amylyx Pharmaceuticals (AMLX) stake by 23% in Q1 2026, selling an estimated $237K and leaving 55,773 shares worth $775K. The position accounts for ﹤0.01% of the portfolio, ranked #2221.

Legal & General Group first reported a position in AMLX in Q1 2022 and has held it in 13 quarters since. The position peaked at $913K in Q3 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Legal & General Group held 55,773 shares of Amylyx Pharmaceuticals worth $775K as of Q1 2026.
  • Legal & General Group sold 16,839 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $237K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2221 holding.
  • Legal & General Group first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 13 quarters since.
  • Legal & General Group's Amylyx Pharmaceuticals position peaked at $913K in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.